Adlai Nortye Ltd. (NASDAQ:ANL) Short Interest Down 13.6% in February

Adlai Nortye Ltd. (NASDAQ:ANL) was the target of a significant drop in short interest during the month of February. As of February 15th, there was short interest totalling 3,800 shares, a drop of 13.6% from the January 31st total of 4,400 shares. Based on an average trading volume of 9,100 shares, the short-interest ratio is currently 0.4 days.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and set a $9.00 price target on shares of Adlai Nortye in a research note on Monday, November 11th.

Adlai Nortye Trading Down 4.3 %

Shares of Adlai Nortye stock opened at $2.20 on Wednesday. The business’s fifty day moving average price is $2.17 and its 200 day moving average price is $2.28. Adlai Nortye has a twelve month low of $1.85 and a twelve month high of $17.48.

About Adlai Nortye

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.